Adagene (ADAG) vs Atrium Therapeutics (RNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Adagene is the larger company by market cap ($138.3 million vs $131.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | RNA |
|---|---|---|
| Share price | $2.06 | $7.67 |
| Market cap | $138.32M | $131.20M |
| 1-day change | -14.17% | -1.92% |
| YTD return | +8.99% | — |
| 1-year return | +17.05% | — |
| 5-year return | -82.60% | — |
| EPS (TTM) | $-0.38 | $-5.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.67M | — |
| Revenue growth (YoY) | +7332.76% | — |
| Net income (latest FY) | $-17.61M | — |
| Operating margin | -279.48% | — |
| Net margin | -229.56% | — |
| 52-week high | $4.85 | $16.77 |
| 52-week low | $1.30 | $7.54 |
| Distance from 52-week high | -57.53% | -54.26% |
| Analyst consensus | none | none |
| Avg. price target upside | +381.07% | +225.95% |
| Average volume | 286.63K | 259.72K |
| Shares outstanding | 67.14M | 17.11M |
| Employees | 128 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Atrium Therapeutics
RNA stock →Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
Health Care · Biotechnology: Pharmaceutical Preparations
ADAG vs RNA FAQ
Which is bigger, Adagene or Atrium Therapeutics?
Adagene (ADAG) is larger, with a market capitalization of $138.32M compared with $131.20M for Atrium Therapeutics (RNA).
Are Adagene and Atrium Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.